secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001861560-26-000003
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent submits NDA to FDA for neladalkib in ALK-positive lung cancer
----------------------------------------------------------------------

- NDA submitted to FDA on April 7, 2026, for neladalkib in TKI pre-treated advanced ALK-positive NSCLC.
- Neladalkib is a novel ALK inhibitor targeting advanced ALK+ non-small cell lung cancer.
- Submission marks regulatory milestone; no additional details on acceptance or review timeline provided.
- Nuvalent (NUVL) expects FDA review of the NDA for potential market approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000186156026000003/0001861560-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000186156026000003/nuvl-20260407.htm
  HTML page:      https://secwatch.observer/filing/0001861560-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer